Grafalon

Grafalon is a rabbit‑derived anti‑T lymphocyte immunoglobulin supplied as a sterile solution for injection. The active ingredient, Anti‑T Lymphocyte Immunoglobulin (Rabbit), is formulated for intravenous use and classified as an immunosuppressant and immunomodulator. Marketed in the European Union, Grafalon is a prescription‑only product intended for hospital administration under medical supervision to modulate cellular immunity in transplant‑related settings. It is administered by qualified clinicians and requires careful monitoring of immune parameters.

Grafalon is indicated for specific immunological challenges associated with organ transplantation and related complications.

- Prevention of acute cellular rejection in kidney, liver, heart, or lung transplants. - Treatment of graft‑versus‑host disease (GVHD) following hematopoietic stem cell transplantation. - Induction therapy to reduce early immune activation in high‑risk transplant recipients. - Adjunctive immunosuppression when conventional agents are contraindicated or insufficient. - Use in clinical protocols requiring profound T‑cell depletion prior to transplantation.

The immunologic activity of Grafalon can produce a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Fever, chills, or rigors during or shortly after infusion. - Transient hypotension or mild hypertension. - Nausea, vomiting, or mild gastrointestinal discomfort. - Headache or fatigue.

Serious: - Severe infusion‑related reactions such as anaphylaxis or bronchospasm. - Cytokine release syndrome presenting with high fever and organ dysfunction. - Profound and prolonged lymphopenia increasing infection risk. - Hemolytic anemia or thrombocytopenia.

Because Grafalon profoundly suppresses cellular immunity, several precautions should be observed before and during therapy.

- Verify patient’s infection status; active bacterial, viral, or fungal infections should be treated prior to administration. - Assess baseline complete blood count and liver function; monitor for cytopenias and hepatic toxicity. - Screen for prior sensitization to rabbit proteins to reduce risk of severe allergic reactions. - Use pre‑medication (e.g., antihistamines, corticosteroids) to mitigate infusion‑related symptoms. - Maintain strict aseptic technique during intravenous infusion to prevent catheter‑related infections. - Counsel patients on signs of infection and advise prompt medical evaluation.

Grafalon may interact with other agents that affect immune function or hemodynamics, requiring careful management.

Avoid: - Concurrent use with live vaccines, as immunosuppression can diminish vaccine efficacy and increase risk. - Co‑administration with other T‑cell depleting antibodies or potent immunosuppressants without dose adjustment.

Use with caution: - Antifungal or antiviral prophylaxis agents, which may require dose modification due to overlapping toxicity. - Drugs that prolong QT interval, as Grafalon‑related electrolyte shifts can increase arrhythmia risk. - Diuretics or antihypertensives, because Grafalon‑induced fluid shifts may affect blood pressure control.